The Debrisoquine Metabolic Phenotype and DNA-Based Assays: Implications of Misclassification for the...
The Debrisoquine Metabolic Phenotype and DNA-Based Assays: Implications of Misclassification for the Association of Lung Cancer and the Debrisoquine Metabolic Phenotype
About this item
Full title
Author / Creator
Publisher
United States: National Institute of Environmental Health Sciences. National Institutes of Health. Department of Health, Education and Welfare
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Institute of Environmental Health Sciences. National Institutes of Health. Department of Health, Education and Welfare
Subjects
More information
Scope and Contents
Contents
Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502 D6. Deficient metabolism is inherited as an autosomal recessive condition. We previously reported in a case-control study that extensive metabolizers of debrisoquine were at greater risk of lung cancer compared to poor and intermediate metabolizers. Cloning of the gene...
Alternative Titles
Full title
The Debrisoquine Metabolic Phenotype and DNA-Based Assays: Implications of Misclassification for the Association of Lung Cancer and the Debrisoquine Metabolic Phenotype
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1519603
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1519603
Other Identifiers
ISSN
0091-6765
E-ISSN
1552-9924
DOI
10.1289/ehp.9298101
